US Patent 11110179 Combination of CD33 antibody drug conjugates with chemotherapeutic agents

Patent 11110179 was granted and assigned to SeaGen on September, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

SeaGen

Current Assignee

SeaGen

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

111101790

Patent Inventor Names

Eric Feldman0

Dana Kennedy0

Date of Patent

September 7, 2021

Patent Application Number

201706020

Date Filed

June 2, 2017

Patent Citations Received

‌

US Patent 11753469 Methods of using bispecific CD33 and CD3 binding proteins

Patent abstract

This invention relates to treatment of cancer using a CD33 antibody drug conjugate in combination with chemotherapeutic agents.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11110179 Combination of CD33 antibody drug conjugates with chemotherapeutic agents

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API